CUSIP: 286221106
Q1 2016 13F Holders as of 31 Mar 2016
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
5,225,587
-
Share change
-
-5,959,280
-
Total reported value
-
$1,669,000
-
Price per share
-
$0.32
-
Number of holders
-
18
-
Value change
-
-$20,789,967
-
Number of buys
-
6
-
Number of sells
-
16
Quarterly Holders Quick Answers
What is CUSIP 286221106?
CUSIP 286221106 identifies EBIO - ELEVEN BIOTHERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2016
-
Previous quarter:
Q4 2015
Recent filing periods for CUSIP 286221106:
Institutional Holders of ELEVEN BIOTHERAPEUTICS INC - COM (EBIO) as of Q1 2016
As of 31 Mar 2016,
ELEVEN BIOTHERAPEUTICS INC - COM (EBIO) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,225,587 shares.
The largest 10 holders included
FLAGSHIP VENTURES FUND 2007, L.P., FLAGSHIP VENTURES FUND IV, L.P., SABBY MANAGEMENT, LLC, BlackRock Institutional Trust Company, N.A., RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, Bank of New York Mellon Corp, BRIDGEWAY CAPITAL MANAGEMENT INC, GEODE CAPITAL MANAGEMENT, LLC, and GOLDMAN SACHS GROUP INC.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.